期刊
JOURNAL OF BIOLOGICAL CHEMISTRY
卷 287, 期 31, 页码 26400-26408出版社
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M112.380998
关键词
-
资金
- National Institutes of Health
- NIGMS [GM-079376]
- Stewart Trust Foundation
- NIEHS [ES-015818]
- American Cancer Society Research professorship
Translesion synthesis is a fundamental biological process that enables DNA replication across lesion sites to ensure timely duplication of genetic information at the cost of replication fidelity, and it is implicated in development of cancer drug resistance after chemotherapy. The eukaryotic Y-family polymerase Rev1 is an essential scaffolding protein in translesion synthesis. Its C-terminal domain (CTD), which interacts with translesion polymerase zeta through the Rev7 subunit and with polymerases kappa, iota, and eta in vertebrates through the Rev1-interacting region (RIR), is absolutely required for function. We report the first solution structures of the mouse Rev1 CTD and its complex with the Pol kappa RIR, revealing an atypical four-helix bundle. Using yeast two-hybrid assays, we have identified a Rev7-binding surface centered at the alpha 2-alpha 3 loop and N-terminal half of alpha 3 of the Rev1 CTD. Binding of the mouse Pol kappa RIR to the Rev1 CTD induces folding of the disordered RIR peptide into a three-turn alpha-helix, with the helix stabilized by an N-terminal cap. RIR binding also induces folding of a disordered N-terminal loop of the Rev1 CTD into a beta-hairpin that projects over the shallow alpha 1-alpha 2 surface and creates a deep hydrophobic cavity to interact with the essential FF residues juxtaposed on the same side of the RIR helix. Our combined structural and biochemical studies reveal two distinct surfaces of the Rev1 CTD that separately mediate the assembly of extension and insertion translesion polymerase complexes and provide a molecular framework for developing novel cancer therapeutics to inhibit translesion synthesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据